planes de pago
¿Quieres analizar varias empresas a la vez? Los planes de pago te permiten comparar hasta 5 acciones lado a lado.
Regístrate
LABT
vs
S&P 500
LABT
S&P 500
En los últimos 12 meses, LABT ha quedado por detrás de S&P 500, con una rentabilidad de -95% frente a un crecimiento de +11% de S&P 500.
Rendimiento de las acciones
LABT vs S&P 500
Diferencia de rendimiento
LABT vs S&P 500
Rendimiento por año
LABT vs S&P 500
Compara la rentabilidad de la acción con su índice de referencia y sus competidores. Obtén información sobre su rendimiento relativo a lo largo del tiempo.
Rendimiento de los competidores
Lakewood-Amedex Biotherapeutics Inc vs pares
Lakewood-Amedex Biotherapeutics Inc
Vista general
Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. The company is headquartered in University Park, Florida and currently employs 5 full-time employees. The company went IPO on 2026-04-23. The firm is focused on addressing unmet needs in the treatment of serious infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, NDM-1, and many others. The firm is engaged in development of its Bisphosphocin class of antimicrobial agents. The firm is exploring additional local drug delivery applications, including complicated urinary tract infections (CAUTI) and pulmonary infections. The firm has a portfolio of compounds that are being profiled for indications such as infected diabetic foot ulcer, urinary tract infections, and pulmonary infections.